Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.

被引：0
|
作者：
Maruzzo, Marco
Basso, Umberto
Diminutto, Alberto
De Giorgi, Ugo
Fratino, Lucia
Lo Re, Giovanni
D'Angelo, Alessandro
Donini, Maddalena
Verderame, Francesco
Ratta, Raffaele
Procopio, Giuseppe
Campadelli, Enrico
Massari, Francesco
Gasparro, Donatello
Macrini, Sveva
Messina, Caterina
Giordano, Monica
Maines, Francesca
Zagonel, Vittorina
Caffo, Orazio
机构：
[1] IRCCS, IOV, Med Oncol 1, Padua, Italy
[2] IRCCS, Ist Oncol Veneto, Padua, Italy
[3] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Natl Canc Ctr CRO, Aviano, Italy
[5] Santa Maria Degli Angeli Gen Hosp, Pordenone, Italy
[6] Civil Hosp, Taormina, Italy
[7] Ist Ospitalieri Cremona, Cremona, Italy
[8] Cervello Hosp, Palermo, Italy
[9] Unicampus Univ, Rome, Italy
[10] Ist Nazl Tumori, Fdn IRCCS, Oncol Unit 1, I-20133 Milan, Italy
[11] Civil Hosp, Lugo Di Romagna, Italy
[12] Univ Verona, Med Oncol, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[13] Univ Hosp Parma, Parma, Italy
[14] Univ Hosp, Udine, Italy
[15] Pope John Paul XXIII Hosp, Med Oncol Unit, Bergamo, Italy
[16] Santa Anna Hosp, Como, Italy
[17] Santa Chiara Hosp, Trento, Italy
[18] IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页数：1
相关论文
共 50 条
  • [31] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
    Martinez-Hernandez, Lucia
    Martinez-Prieto, Marcela
    Galvan-Salazar, Gabriel
    GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
  • [32] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [33] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [34] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
    Harland, Stephen
    Staffurth, John
    Molina, Arturo
    Hao, Yanni
    Gagnon, Dennis D.
    Sternberg, Cora N.
    Cella, David
    Fizazi, Karim
    Logothetis, Christopher J.
    Kheoh, Thian
    Haqq, Christopher M.
    de Bono, Johann S.
    Scher, Howard I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (17) : 3648 - 3657
  • [38] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [40] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345